Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Organisation › Details

Galapagos (Group)

Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of GLPG0634. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2b studies in RA and in Phase 2 in Crohn’s disease. GLPG1205, a first-in-class inhibitor of GPR84, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690 is a compound that targets pulmonary diseases and is currently in a Phase 1 trial. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. *

 

Period Start 1999-06-01 established
Period End 2005-04-15 renamed before
  Predecessor Crucell (Group)
Product Industry genomics/genetics
Persons Person van de Stolpe, Onno (Galapagos 200501 CEO)
  Person 2 Filius, Bart (Galapagos 201412– CFO before Sanofi VP CFO at Sanofi Europe)
     
Region Region Mechelen
  Country Belgium
  Street Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3
  City 2800 Mechelen
  Tel +32-15342900
    Address record changed: 2018-07-24
     
Basic data Employees E: 501 to 1,000 (2017-02-23)
  Currency EUR
  Annual sales 151,600,000 (revenues, consolidated (2016) 2016-12-31)
  Profit 54,000,000 (2016-12-31)
  Cash 980,900,000 (2016-12-31)
     
    * Document for �About Section�: Galapagos N.V.. (2/11/15). "Press Release: Galapagos Receives €1.6 Million IWT Grant for Hepatitis B Program". Mechelen.
     
   
Record changed: 2018-10-30

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for Galapagos (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top